PolyPeptide Group AG (SIX: PPGN)

https://www.polypeptide.com

LinkedIn: https://www.linkedin.com/company/60184

PolyPeptide Group AG with its consolidated subsidiaries (“PolyPeptide”) is a focused Contract Development & Manufacturing Organization (CDMO) for peptide- and oligonucleotide-based active pharmaceutical ingredients. By supporting its customers mainly in pharma and biotech, it contributes to the health of millions of patients across the world. PolyPeptide offers products and services from pre-clinical through to commercial stages, including generics. Its active custom projects pipeline reflects the opportunities from novel drug therapies in development to fight both widespread and rare diseases. Dating back to 1952, PolyPeptide today runs a global network of six cGMP-certified facilities in Europe, the U.S. and India. PolyPeptide’s shares (SIX: PPGN) are listed on SIX Swiss Exchange. *

	Start	2023-05-09 existent
	Group	PolyPeptide (Group)
	Industry	peptide synthesis
	Industry 2	contract manufacturing (biologicals)

	Region	Baar ZG
	Country	Switzerland
	Street	24 Neuhofstr.
	City	6340 Baar ZG
	Tel	+41-43-502-0580
		Address record changed: 2023-05-11

Basic data	Employees	F: 1,001 to 5,000 (2023-05-10)
	Currency	CHF
	Annual sales	9,960,000 (income, total, consolidated (2022) 2022-12-31)
	Profit	-1,163,631,000 (2022-12-31)
	Cash	10,061,000 (2022-12-31)

		* Document for »About Section«: Numaferm GmbH. (5/9/23). "Press Release: PolyPeptide and Numaferm Announce Partnership to Leverage Their Expertise for the More Sustainable Production of Peptide-based APIs". Baar & Düsseldorf.

		Record changed: 2023-10-05